삼성바이오로직스

Check out the exclusive interviews where we share our latest insights and continued commitment to delivering innovative solutions with new therapeutic modalities. 🤝 “We’re keen to partner with mRNA biotechs as well as lipid nanoparticle platform companies to bring vaccines and therapeutics to clients worldwide,” says Haenaem Kwon, Director of the mRNA Technology Group. “Let’s work together to tackle more disease mechanisms with new modalities.” Read more in our Newsroom story: https://lnkd.in/eyYWTjkb #CDMO #Partnership #SamsungBiologics #mRNA #saRNA #LNP

As the biopharmaceutical industry continues to emphasize the criticality of a tailored Chemistry, Manufacturing, and Controls (CMC) strategy for faster drug approvals without compromising quality, learning how to design the right CMC approach is essential. Our CMC experts Yoonsik Kim and Steven Lal, PhD walk through tangible ways to build a customized drug development strategy and how it can help promptly overcome challenges, in their article in International Biopharmaceutical Industry (pages 40-42): https://lnkd.in/djvWkKbu #CMC #DrugDevelopment #CDMO #SamsungBiologics

By integrating sequence variant analysis (SVA) at strategic points within the cell line and process development workflows, Samsung Biologics not only reduces time and costs but also enhances the quality of the final product. 📊 In the latest discussion with Contract Pharma, Kyoungmin Lee, Senior Scientist of Structure Analytics, shares the role SVA plays in biologics drug development, the capabilities and tools needed to accelerate SVA, address risks, and more. Read on to learn about how we can be your strategic partner in drug development: https://lnkd.in/e6ezvkdU #DrugDevelopment #CDMO #SamsungBiologics

The biopharmaceutical industry is evolving with ideas for more competitive technologies and better ways to achieve drug approval faster, especially in response to the increasing demand for innovative therapeutics. Taeheui Lee, Vice President and Head of Antibody Cell Culture Process Development, and Sungyul Lee, Senior Director of the Gene Therapy Technology Lab, share their thoughts with Pharma's Almanac on: ⏳ Collaborative ways to expedite drug approval processes: https://lnkd.in/eNyZ8gBC 💡 Technology required for overcoming mRNA challenges: https://lnkd.in/eKzhv5Mz #DrugApproval #CDMO #mRNA #SamsungBiologics

In our March newsletter, we highlight our technologies and experts driving innovation in biologics. From advancing drug development and ADC capabilities to enhancing operational excellence, read the latest edition and learn more. 👉🏻 Sign up today and get your monthly update! https://lnkd.in/gzjdWn9R #SamsungBiologics #DrivenForLife

Messenger RNAs (mRNAs) have opened up a new frontier in developing innovative therapeutics beyond vaccines. At the same time, challenges regarding its intricacy in technology and quality procedures remain to be solved. Two of our veteran mRNA scientists, Sungyul Lee and Eunseo Lee, walk through a list of key technologies and earned know-how required to develop mRNA drugs right the first time, and advise how partnering with the right CDMO can expedite the development of your mRNA project without compromising quality. https://lnkd.in/eVCdvUhv #mRNA #CDMO #SamsungBiologics #Quality

What are the trends shaping biopharma in 2025? Our ADC process development expert SongYoung Kim shares his insights on overcoming ADC manufacturing and supply chain challenges. 🗨️ ”Since ADCs consist of an antibody, a cytotoxic payload, and a chemical linker, companies tend to rely on different vendors for each component, complicating the supply chain. Biotech and pharmaceutical companies are overcoming these challenges by partnering with CDMOs that have specialized facilities for ADC manufacturing and the analytical capabilities necessary to support every step of the journey.“ Read more in the latest Pharma Manufacturing article: https://lnkd.in/gpY9nq-n #Biopharma #ADCs #SupplyChain #Biomanufacturing #SamsungBiologics

Finding the right CDMO partner with the capacity and capabilities to meet your needs is essential. Join Mark Thompson, PhD and other industry leaders for a webinar featuring insights on the role of capacity in large molecule drug substance development and manufacturing. This interactive session will feature short presentations followed by a live Q&A, helping you connect with CDMOs and better understand their services. Register now to secure your spot! 📅 Tuesday, 22 April 🕝 10am ET | 4pm CET | 7am PT 📍 Registration: https://lnkd.in/gkvh7RDz

Meet our ADC expert Marc Studer! 🌟 Marc sat down to share his strategic vision for ADC services at Samsung Biologics, specifying plans for next-generation therapeutics in partnership with our clients and operations teams. Learn more about our ADC services and connect with us: https://lnkd.in/gE-aCSMV #ExpertInterview #ADC #SamsungBiologics #CDMO #Partnership

People are at the core of what we value at Samsung Biologics. We continue to build on people excellence, offering various opportunities for our employees to learn and grow while supporting them in sustaining a healthy lifestyle. ✨ Read more about how our employees pursue growth in a rapidly growing and constructive work environment: https://lnkd.in/eyyrAE6Z #SamsungBiologics #CDMO #innovation #growth #health #WorkLifeBalance